| Cancer regression in patients after transfer of genetically engineered lymphocytes RA Morgan, ME Dudley, JR Wunderlich, MS Hughes, JC Yang, ... Science 314 (5796), 126-129, 2006 | 4112 | 2006 |
| Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes ME Dudley, JR Wunderlich, PF Robbins, JC Yang, P Hwu, ... Science 298 (5594), 850-854, 2002 | 3727 | 2002 |
| Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2 RA Morgan, JC Yang, M Kitano, ME Dudley, CM Laurencot, ... Molecular therapy 18 (4), 843-851, 2010 | 2820 | 2010 |
| Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy SA Rosenberg, JC Yang, RM Sherry, US Kammula, MS Hughes, ... Clinical cancer research 17 (13), 4550-4557, 2011 | 2608 | 2011 |
| Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer E Tran, S Turcotte, A Gros, PF Robbins, YC Lu, ME Dudley, ... Science 344 (6184), 641-645, 2014 | 2417 | 2014 |
| Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma SA Rosenberg, JC Yang, DJ Schwartzentruber, P Hwu, FM Marincola, ... Nature medicine 4 (3), 321-327, 1998 | 2235 | 1998 |
| Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma ME Dudley, JR Wunderlich, JC Yang, RM Sherry, SL Topalian, NP Restifo, ... Journal of clinical oncology: official journal of the American Society of …, 2005 | 2118 | 2005 |
| Adoptive cell transfer: a clinical path to effective cancer immunotherapy SA Rosenberg, NP Restifo, JC Yang, RA Morgan, ME Dudley Nature Reviews Cancer 8 (4), 299-308, 2008 | 2086 | 2008 |
| Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired M Ahmadzadeh, LA Johnson, B Heemskerk, JR Wunderlich, ME Dudley, ... Blood, The Journal of the American Society of Hematology 114 (8), 1537-1544, 2009 | 2043 | 2009 |
| Adoptive immunotherapy for cancer: harnessing the T cell response NP Restifo, ME Dudley, SA Rosenberg Nature Reviews Immunology 12 (4), 269-281, 2012 | 2027 | 2012 |
| Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1 PF Robbins, RA Morgan, SA Feldman, JC Yang, RM Sherry, ME Dudley, ... Journal of Clinical Oncology 29 (7), 917, 2011 | 1904 | 2011 |
| Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric … JN Kochenderfer, ME Dudley, SH Kassim, RPT Somerville, RO Carpenter, ... Journal of clinical oncology 33 (6), 540, 2015 | 1896 | 2015 |
| B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells JN Kochenderfer, ME Dudley, SA Feldman, WH Wilson, DE Spaner, ... Blood, The Journal of the American Society of Hematology 119 (12), 2709-2720, 2012 | 1783 | 2012 |
| Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen LA Johnson, RA Morgan, ME Dudley, L Cassard, JC Yang, MS Hughes, ... Blood, The Journal of the American Society of Hematology 114 (3), 535-546, 2009 | 1716 | 2009 |
| Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens ME Dudley, JC Yang, R Sherry, MS Hughes, R Royal, U Kammula, ... Journal of Clinical Oncology 26 (32), 5233, 2008 | 1639 | 2008 |
| Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 JN Kochenderfer, WH Wilson, JE Janik, ME Dudley, M Stetler-Stevenson, ... Blood, The Journal of the American Society of Hematology 116 (20), 4099-4102, 2010 | 1595 | 2010 |
| Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy RA Morgan, N Chinnasamy, D Abate-Daga, A Gros, PF Robbins, Z Zheng, ... Journal of immunotherapy 36 (2), 133-151, 2013 | 1279 | 2013 |
| T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis MR Parkhurst, JC Yang, RC Langan, ME Dudley, DAN Nathan, ... Molecular Therapy 19 (3), 620-626, 2011 | 1183 | 2011 |
| PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors A Gros, PF Robbins, X Yao, YF Li, S Turcotte, E Tran, JR Wunderlich, ... The Journal of clinical investigation 124 (5), 2246-2259, 2014 | 1086 | 2014 |
| A pilot trial using lymphocytes genetically engineered with an NY-ESO-1–reactive T-cell receptor: long-term follow-up and correlates with response PF Robbins, SH Kassim, TLN Tran, JS Crystal, RA Morgan, SA Feldman, ... Clinical Cancer Research 21 (5), 1019-1027, 2015 | 866 | 2015 |
Steven A RosenbergNCIVerified email at nih.gov
